Ipsen confirms departure of research and development head

Pharmaceutical Company Restructures

Ipsen has announced that Claude Bertrand, its executive vice-president for research and development and chief scientific officer, will leave the company on January 2nd 2017.

Mr Bertrand has occupied this role for the last seven years, but has elected to leave Ipsen to pursue a new opportunity with another company.

“Ipsen has appointed Dr Alexandre Lebeaut as the new leader of its research and development unit after confirming the departure of Claude Bertrand.“

Dr Alexandre Lebeaut has been appointed as the new interim head of the research and development division, at least until the firm has named a permanent successor to Mr Bertrand.

Having joined Ipsen in 2012, Dr Lebeaut currently serves as its senior vice-president for global drug development and can boast considerable medical and managerial experience, having spent more than 20 years working for large pharmaceutical and biotechnology companies.

David Meek, chief executive officer of Ipsen, said: "On behalf of the company, I would like to thank Dr Bertrand for his significant contribution to leading the research and development organisation during the past seven years."

Mr Meek took over as the company's chief executive earlier this year, succeeding Marc de Garidel.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Pharmaceutical
Return to news

Tags